Entities / Company
Karuna Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 9
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.Well supported3 reports1 development inside
-
Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.Some support2 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Karuna Therapeutics this week
News at the entities that move Karuna Therapeutics most-
Bristol-Myers Squibb StructuralBristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Moves Karuna Therapeutics
Connections
The 2 strongest of 9, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Bristol-Myers Squibb Structural
Bristol-Myers Squibb acquired Karuna Therapeutics, establishing Karuna as a subsidiary.
-
Andrew Miller Transactional
Andrew Miller previously held the leadership role in R&D at Karuna Therapeutics.
History
Events by the month they beganJune 2026
3 events- Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
- Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.
- The acquisition of Karuna Therapeutics by AbbVie was validated on August 20, 2025.